Boston/West Haven-based biotech closes $75M in Series B financing
Normunity Inc., a biotech creating anti-cancer immunotherapies, announced Monday it has closed a $75 million Series B financing round. The round was co-led by new investors Samsara BioCapital and Enavate Sciences, along with Regeneron Ventures, Pfizer …